Evaluating Admilparant in the ALOFT-IPF Program: Translating the LPA1 Pathway into Clinical Potential
9:30 am - Wednesday 30th September 2026
- Exploring the biological rationale for targeting the lysophosphatidic acid receptor-1 (LPA1) pathway in pulmonary fibrosis, including its role in fibroblast recruitment, activation, and extracellular matrix deposition driving disease progression
- Discussing the clinical development of admilparant (BMS-986278) as a first-in class oral LPA1 antagonist, and what differentiates this approach within the current antifibrotic landscape
- Sharing perspectives on the anticipated impact of ongoing Phase 3 programs, including how LPA1 inhibition could shape future treatment paradigms and combination strategies in IPF